IN2012DN02379A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN02379A IN2012DN02379A IN2379DEN2012A IN2012DN02379A IN 2012DN02379 A IN2012DN02379 A IN 2012DN02379A IN 2379DEN2012 A IN2379DEN2012 A IN 2379DEN2012A IN 2012DN02379 A IN2012DN02379 A IN 2012DN02379A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- liquid vehicle
- acceptable liquid
- suspension formulation
- oral suspension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
An oral suspension formulation comprising eslicarbazepine acetate and a pharmaceutically acceptable liquid vehicle.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24119509P | 2009-09-10 | 2009-09-10 | |
PCT/PT2010/000038 WO2011031176A1 (en) | 2009-09-10 | 2010-09-10 | Oral suspension formulations of esclicarbazepine acetate |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2012DN02379A true IN2012DN02379A (en) | 2015-08-21 |
Family
ID=43037794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN2379DEN2012 IN2012DN02379A (en) | 2009-09-10 | 2010-09-10 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20130040939A1 (en) |
EP (1) | EP2475357A1 (en) |
JP (1) | JP2013504569A (en) |
KR (1) | KR20120094473A (en) |
CN (1) | CN102612359A (en) |
AR (1) | AR078283A1 (en) |
AU (1) | AU2010293105A1 (en) |
BR (1) | BR112012005254A2 (en) |
CA (1) | CA2773249A1 (en) |
IN (1) | IN2012DN02379A (en) |
MX (1) | MX2012002831A (en) |
RU (1) | RU2012113844A (en) |
WO (1) | WO2011031176A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0700773D0 (en) | 2007-01-15 | 2007-02-21 | Portela & Ca Sa | Drug therapies |
WO2011014084A1 (en) | 2009-07-27 | 2011-02-03 | Bial - Portela & Ca., S.A. | Use of 5h-dibenz / b, f/ azepine-5-carboxamide derivatives for treating fibromyalgia |
US9750747B2 (en) | 2011-08-26 | 2017-09-05 | Bail-Portela & Ca, S.A. | Treatments involving eslicarbazepine acetate or eslicarbazepine |
GB201306095D0 (en) * | 2013-04-04 | 2013-05-22 | Bial Portela & Ca Sa | New treatments |
JP6122815B2 (en) * | 2014-02-20 | 2017-04-26 | ライオン株式会社 | Oral preparation and method for producing the same |
JP6786240B2 (en) * | 2016-03-31 | 2020-11-18 | 小林製薬株式会社 | Viscous oral composition |
WO2019058353A1 (en) * | 2017-09-25 | 2019-03-28 | Jubilant Generics Limited | Modified release suspension of eslicarbazepine |
US11318145B2 (en) * | 2018-09-25 | 2022-05-03 | Jubilant Generics Limited | Eslicarbazepine suspension |
WO2019058354A1 (en) * | 2017-09-25 | 2019-03-28 | Jubilant Generics Limited | Eslicarbazepine suspension |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8618847D0 (en) * | 1986-08-01 | 1986-09-10 | Smith Kline French Lab | Pharmaceutical formulations |
JP3844491B2 (en) * | 1993-10-01 | 2006-11-15 | シンテックス(ユー・エス・エイ)インコーポレイテッド | Mycophenolate mofetil high-dose oral suspension |
US6184220B1 (en) * | 1998-03-27 | 2001-02-06 | Boehringer Ingelheim Pharma Kg | Oral suspension of pharmaceutical substance |
GB9930058D0 (en) * | 1999-12-20 | 2000-02-09 | Novartis Ag | Organic compounds |
US20020028794A1 (en) * | 2000-07-21 | 2002-03-07 | Brubaker Greg Allen | Megestrol acetate suspension |
US6510799B2 (en) * | 2001-07-02 | 2003-01-28 | Magna Force, Inc. | Apparatus, systems and methods for levitating and moving objects |
US7300670B2 (en) * | 2002-04-03 | 2007-11-27 | Unilab Pharmatech, Ltd. | Oral suspension formulation |
JP2005530822A (en) * | 2002-06-17 | 2005-10-13 | ターロ ファーマシューティカルズ ユーエスエイ インコーポレイテッド | Ibuprofen suspension |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
US7118508B2 (en) * | 2004-07-28 | 2006-10-10 | General Motors Corporation | Planetary transmissions having three interconnected gear members and clutched input members |
WO2006018814A2 (en) * | 2004-08-16 | 2006-02-23 | Ranbaxy Laboratories Limited | Oral liquid suspensions of metaxalone |
US20060252745A1 (en) * | 2005-05-06 | 2006-11-09 | Almeida Jose L D | Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use |
EP2380575B1 (en) | 2005-05-06 | 2015-02-25 | Bial-Portela & CA, S.A. | Eslicarbazepine acetate and use |
WO2007007182A2 (en) * | 2005-07-08 | 2007-01-18 | Aurobindo Pharma Limited | Solid and liquid dosage forms of an antiepileptic agent |
-
2010
- 2010-09-10 KR KR1020127008885A patent/KR20120094473A/en not_active Application Discontinuation
- 2010-09-10 CN CN2010800402118A patent/CN102612359A/en active Pending
- 2010-09-10 WO PCT/PT2010/000038 patent/WO2011031176A1/en active Application Filing
- 2010-09-10 JP JP2012528773A patent/JP2013504569A/en active Pending
- 2010-09-10 RU RU2012113844/15A patent/RU2012113844A/en not_active Application Discontinuation
- 2010-09-10 BR BR112012005254A patent/BR112012005254A2/en not_active Application Discontinuation
- 2010-09-10 EP EP10757859A patent/EP2475357A1/en not_active Withdrawn
- 2010-09-10 IN IN2379DEN2012 patent/IN2012DN02379A/en unknown
- 2010-09-10 MX MX2012002831A patent/MX2012002831A/en not_active Application Discontinuation
- 2010-09-10 AU AU2010293105A patent/AU2010293105A1/en not_active Abandoned
- 2010-09-10 US US13/394,414 patent/US20130040939A1/en not_active Abandoned
- 2010-09-10 CA CA2773249A patent/CA2773249A1/en not_active Abandoned
- 2010-09-10 AR ARP100103320A patent/AR078283A1/en unknown
-
2017
- 2017-10-17 US US15/785,890 patent/US20180256594A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BR112012005254A2 (en) | 2016-03-15 |
CA2773249A1 (en) | 2011-03-17 |
AR078283A1 (en) | 2011-10-26 |
WO2011031176A1 (en) | 2011-03-17 |
JP2013504569A (en) | 2013-02-07 |
AU2010293105A8 (en) | 2012-07-19 |
AU2010293105A1 (en) | 2012-04-05 |
EP2475357A1 (en) | 2012-07-18 |
CN102612359A (en) | 2012-07-25 |
US20180256594A1 (en) | 2018-09-13 |
MX2012002831A (en) | 2012-05-08 |
RU2012113844A (en) | 2013-10-20 |
KR20120094473A (en) | 2012-08-24 |
US20130040939A1 (en) | 2013-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN02379A (en) | ||
EP2588163A4 (en) | Medicament delivery device | |
EP2512564A4 (en) | Medicament delivery device | |
TN2012000195A1 (en) | Solid dispersion of rifaximin | |
AU2010260569A8 (en) | Medicament container holder arrangement | |
EP2442856A4 (en) | Medicament container holder arrangement | |
EP2459112B8 (en) | Oral care device | |
EP2396070A4 (en) | Drug delivery through hydrogel plugs | |
IL205160A0 (en) | Oral dosage forms comprising licarbazepine acetate | |
ZA201108384B (en) | Aqueous pharmaceutical compositions containing borate-polyol complex | |
EP2360173A4 (en) | Cytotoxic t cell epitope peptide for sars coronavirus, and use thereof | |
IL217500A0 (en) | Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them | |
EP2481682A4 (en) | Drug package bags and sheet for the bags | |
ZA201107019B (en) | Menthol-derivative compounds and use thereof as oral and systemic active agents | |
IL212603A0 (en) | Combined drug administration | |
ZA201204670B (en) | Seven-membered ring compound and pharmaceutical use therefor | |
WO2010120817A3 (en) | Nanochanneled device and related methods | |
WO2010148314A3 (en) | Preparation of esomeprazole and its pharmaceutically acceptable salts | |
IL220839B (en) | 3-phenylamino-9-azabicyclo[3.3.1]nonane derivatives and pharmaceutical compositions comprising them | |
ZA201005396B (en) | 17-hydroxy-19-nor-21-carboxylic acid-steroid y-lactone derivative,use thereof,and medicament containing the derivative | |
AU2014233620B2 (en) | Oral care system | |
AU2008904116A0 (en) | Capsule Delivery Instrument | |
AU2009903559A0 (en) | An administration set flow condition monitor | |
AU2009904280A0 (en) | Dental container | |
GB0906003D0 (en) | Oral drug formulation |